Synovial Sarcoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Synovial Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions.
Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.
The Synovial Sarcoma drugs in development market research report provide comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Synovial Sarcoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 57 molecules, with 53 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Synovial Sarcoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Synovial Sarcoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Synovial Sarcoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncAccuronix Therapeutics Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Advenchen Laboratories LLC
Akeso Inc
ANTUREC Pharmaceuticals GmbH
BioAtla Inc
Biogenera SpA
BioLineRx Ltd
Boehringer Ingelheim International GmbH
Chia Tai Tianqing Pharmaceutical Group Co Ltd
CoBioRes NV
Cue Biopharma Inc
Eisai Co Ltd
Elevar Therapeutics Inc
F. Hoffmann-La Roche Ltd
Foghorn Therapeutics Inc
Idaho State University
Immatics NV
Immunocore Holdings Plc
Incyte Corp
Inhibrx Inc
Innovative Cellular Therapeutics Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Karyopharm Therapeutics Inc
Lixte Biotechnology Holdings Inc
Lyell Immunopharma Inc
Merck & Co Inc
Merck KGaA
Mirati Therapeutics Inc
Moleculin Biotech Inc
NKGen Biotech Inc
Ohara Pharmaceutical Co Ltd
OncoTherapy Science Inc
OrphAI Therapeutics Inc
Pharma Mar SA
Sapience Therapeutics Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Syena
Takara Bio Inc
TCR Cure Biopharma Technology Co Ltd
United Immunity Co Ltd
University Hospital Tubingen
University of South Australia
Xiangxue Life Sciences
Zelluna Immunotherapy AS
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Synovial Sarcoma reports